Live Breaking News & Updates on Pharmaceutical Group Limited

Stay updated with breaking news from Pharmaceutical group limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ITM Isotope Technologies Munich SE: ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater China Area

Grand Pharma has licensed the development, manufacturing and commercialization rights of ITM's Targeted Radionuclide Therapeutic candidates ITM-11 (n.c.a 177Lu-edotreotide) and ITM-41 (n.c.a 177Lu-zoledronate) ....

Hong Kong , Valeria Fisher , Ben Orzelek , Steffen Schuster , Julia Hofmann Susanne Karlsson , Frank Zhou , Group Limited , Corporate Communications , Trophic Communications , Grand Pharma , Radionuclide Therapeutic , Greater China , Technologies Munich , Grand Pharmaceutical Group Limited , Chief Executive Officer , Targeted Radionuclide Therapy , Radionuclide Therapy , Pharmaceutical Group Limited , Nose Throat , Hofmann Susanne Karlsson , Relations Director ,

ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater China Area

Press release content from Business Wire. The AP news staff was not involved in its creation. ....

Hong Kong , Valeria Fisher , Ben Orzelek , Steffen Schuster , Julia Hofmann Susanne Karlsson , Frank Zhou , Contactcorporate Communications , Group Limited , Corporate Communications , Trophic Communications , Media Requeststrophic Communications , Technologies Munich , Grand Pharmaceutical Group Limited , Chief Executive Officer , Greater China , Targeted Radionuclide Therapy , Radionuclide Therapy , Pharmaceutical Group Limited , Media Requeststrophic , Pharmaceutical Group , Business Wire , Licensing Agreements ,

Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and C

Search jobs
28-Jun-2021
Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer s Disease in Greater China
DGAP-News: Vivoryon Therapeutics N.V.
/ Key word(s): Agreement
29.06.2021 / 01:03
The issuer is solely responsible for the content of this announcement.
Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer s Disease in Greater China
Halle (Saale)/Munich, Germany and Nanjing, China, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and Simcere Pharmaceutical Group Ltd (HKEX: 2096) (Simcere) today announced that they have entered into a ....

Ekevin Oliver , Jason Bao , Sophia Hergenhan , Manuela Bader , Michael Schaeffer , Simcere Announce Strategic Regional Licensing Partnership To , Head Of Global Business Development At Simcere , Simcere Pharmaceutical Group , Trophic Communications , Simcere Pharmaceutical Group Ltd , Distribution Services , Treat Alzheimer , Euronext Amsterdam , Greater China , Chief Business , Senior Vice President , Global Business Development , Pharmaceutical Group Limited , Simcere Pharmaceutical Group Limited , Board Secretary , Corporate News , Regulatory Announcements , கெவின் ஆலிவர் , ஜேசன் பாவோ , மைக்கேல் ஸ்கேஃபர் , விநியோகம் சேவைகள் ,